XTLB (XTL Biopharmaceuticals) Long-Term Debt: $0.00 Mil (As of Dec. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
26 GF Score
Price $3.09
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Long-Term Debt?

XTL Biopharmaceuticals XTLB +16.30% 26 Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

XTL Biopharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2025 was $0.00 Mil.

XTL Biopharmaceuticals  (NAS:XTLB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

XTL Biopharmaceuticals Long-Term Debt Related Terms

XTL Biopharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Long-Term Debt Chart

XTL Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTL Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTLB
26GF Score
XTL Biopharmaceuticals Ltd XTLB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Long-Term Debt of $0.00 Mil as of Dec. 2025.
Is XTL Biopharmaceuticals' Long-Term Debt too high?
XTL Biopharmaceuticals' current Long-Term Debt is $0.00 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Long-Term Debt compare to VRTX and REGN?
XTL Biopharmaceuticals' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. XTL Biopharmaceuticals's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score

Get the complete analysis for XTLB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price